Evidence map›Paper›PMID 36986112›Full record

ReviewNutrients2023

A Microbial-Based Approach to Mental Health: The Potential of Probiotics in the Treatment of Depression.

Dinyadarshini Johnson, Vengadesh Letchumanan, Chern Choong Thum, Sivakumar Thurairajasingam, Learn-Han Lee

Registry-linked trialAbstract readReview
In one paragraph

Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06496438 (Psychobiotics Ameliorate Anxiety and Depression Status in Patients Under Chemotherapy for Gastrointestinal Malignancies), which is not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06496438 naunknown statusnot on this map

Psychobiotics Ameliorate Anxiety and Depression Status in Patients Under Chemotherapy for Gastrointestinal Malignancies

TypeinterventionalSponsorAristotle University Of ThessalonikiRan2023 to 2025Enrolled270ConditionsDepression, Anxiety Disorder, Probiotics, Gastrointestinal CancerArmsPsychobiotics, Placebo
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Microorganisms · 2025
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dinyadarshini JohnsonNovel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia.ORCID 0000-0002-9117-5388
Vengadesh LetchumananNovel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia.ORCID 0000-0002-2145-6854
Chern Choong ThumDepartment of Psychiatry, Hospital Sultan Abdul Aziz Shah, Persiaran Mardi-UPM, Serdang 43400, Malaysia.ORCID 0000-0002-5032-0980
Sivakumar ThurairajasingamClinical School Johor Bahru, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Johor Bahru 80100, Malaysia.
Learn-Han LeeNovel Bacteria and Drug Discovery Research Group (NBDD), Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Malaysia.ORCID 0000-0002-8589-7456

Funding

Jeffrey Cheah School of Medicine and Health Sciences (JCSMHS) SEED Fund 2020Jeffrey Cheah School of Medicine and Health Sciences (JCSMHS) Early Career Researcher Grant 2021 ECR000021Jeffrey Cheah School of Medicine and Health Sciences (JCSMHS) Strategic Grant 2021 STG000079
6 · The paper itself

Abstract

Probiotics are currently the subject of intensive research pursuits and also represent a multi-billion-dollar global industry given their vast potential to improve human health. In addition, mental health represents a key domain of healthcare, which currently has limited, adverse-effect prone treatment options, and probiotics may hold the potential to be a novel, customizable treatment for depression. Clinical depression is a common, potentially debilitating condition that may be amenable to a precision psychiatry-based approach utilizing probiotics. Although our understanding has not yet reached a sufficient level, this could be a therapeutic approach that can be tailored for specific individuals with their own unique set of characteristics and health issues. Scientifically, the use of probiotics as a treatment for depression has a valid basis rooted in the microbiota-gut-brain axis (MGBA) mechanisms, which play a role in the pathophysiology of depression. In theory, probiotics appear to be ideal as adjunct therapeutics for major depressive disorder (MDD) and as stand-alone therapeutics for mild MDD and may potentially revolutionize the treatment of depressive disorders. Although there is a wide range of probiotics and an almost limitless range of therapeutic combinations, this review aims to narrow the focus to the most widely commercialized and studied strains, namely

Indexed as

Major Depressive DisorderProbioticsBifidobacteriumDepressionHumansMental Healthdepressiongut microbesmajor depressive disorderprecisionprobioticspsychiatry

Identifiers

PMID36986112
PMCPMC10053794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.